Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
From Overpowered to Coordinated: Individual Accounts of Cleaning up - 2China's Normal Ponders: A Visual Excursion
- 3‘Risk children’s lives for some extra manpower’: IRGC recruits 12 year olds to fill personnel gaps
- 4German state railway loss widens, passengers warned of trouble ahead
- 5Red Crescent: More than 100,000 civilian structures damaged in Iran
- What's your #1 tone
- New dinosaur tracks in Italy illustrate herds moving in unison
- Understanding Successful Compromise Standards to Cultivate Agreeable Connections
- NASA's Apollo 8 moonshot saved 1968. Could Artemis 2 do the same in 2026?
- Finding the Universe of Craftsmanship: Individual Encounters in Imagination
- France honors the victims of the Paris attacks' night of terror 10 years on
- Robert Irwin on winning 'Dancing With the Stars' 10 years after sister Bindi: 'This was everything I dreamed it would be and so much more'
- Everyone knows F1 is for the girls. I wandered into the Las Vegas desert to find out why.
- UK can legally stop shadow fleet tankers, ministers believe
